BioSpace News Archive

T-Cure Bioscience, Inc. announced that the Company has entered into an exclusive, worldwide license with the National Cancer Institute for intellectual property related to a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, for the treatment of KK-LC-1-expressing malignancies, such as gastric, lung, and breast cancers.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in Canada are completed with expected public reimbursement to roll out in the respective provinces over the coming months.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 19 th Annual Needham Healthcare Conference. The conference is being conducted with a virtual format and the presentation will take place on Tuesday, April 14, 2020 at 1:30pm Eastern Time. A live webcast of the presenta

Emerald Bioscience, Inc. today announced that the company has accepted an invitation to join the Alliance for Biosecurity. The Alliance, based in Washington, DC, is

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has received positive feedback from Health Canada on the Company’s plan to conduct a phase 2 COVID-19 clinical study in Canada, with its repurposed drug NP-120 (Ifenprodil).

Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE ® 327 in 40 healthy subjects as a single ascending dose Estimated start-to-completion with data read-outs less than 12 months from now First patients expected to be dosed in second half of 2020

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate and leukemia, today announced it will be presenting at the 19th Annual Needham Healthcare Conference at 3:30

Greenphire, the global leader in financial software for clinical trials, today announced the launch of its ConneX Patient Direct service to enable global clinical trial sites to continue their critical work and patient support in an effort to offset the impact of COVID-19

Global Health Trax has expanded their product line once again, adding a third tier to their venerable series of probiotic supplements.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported its pipeline of MyoPro candidates continued to grow during the first quarter of 2020, with more than 700 candidates awaiting insurance reimbursement authorization as of March 31, 2020. This compares